Back to News
Market Impact: 0.4
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Source: PR Newswire
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
The company reported Q3 2026 total revenue of $358 million, including $276 million in product revenue. It raised full-year 2026 total revenue guidance to $1.29–$1.32 billion and product revenue guidance to $960–$990 million.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Norwegian shares surge 13% on earnings beat, guidance raise
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates